&nbsp;

Drugs Used:

lenalidomide,

dexamethasone

Quick Link(s):

Regimen Monograph

May 2022

Regimen

DOCE+PERT+TRAS

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer

New Drug Funding Program

Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Sep 2022

Regimen

DABR

Cancer Type:

Skin,

Melanoma

Intent: Palliative

Funding:

Exceptional Access Program

daBRAfenib - As monotherapy for the treatment of patients with BRAF V600 mutation-positive unresectable melanoma or metastatic disease, according to specific criteria

Drugs Used:

daBRAFenib

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

DABRTRAM

Cancer Type:

Skin,

Melanoma

Intent: Palliative

Funding:

Exceptional Access Program

daBRAfenib - In combination with trametinib for the treatment of BRAF V600 mutation-positive, unresectable or metastatic melanoma, based on criteria

Exceptional Access Program

trametinib - In combination with dabrafenib for the treatment of BRAF V600 mutation-positive, unresectable or metastatic melanoma, according to specific clinical criteria

Drugs Used:

daBRAFenib,

trametinib

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

DARA

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Drugs Used:

daratumumab (Unfunded)

Quick Link(s):

Regimen Monograph

Sep 2022

Regimen

DABRTRAM

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Drugs Used:

daBRAFenib (Unfunded),

trametinib (Unfunded)

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

DARADEXALENA

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Daratumumab - In Combination with Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma

New Drug Funding Program

Daratumumab in Combination with Lenalidomide and Dexamethasone for Newly Diagnosed Transplant Ineligible Multiple Myeloma

ODB - General Benefit

dexamethasone

ODB Limited Use

lenalidomide - For the treatment of patients with multiple myeloma, who are deemed to be lenalidomide sensitive, and/or have not experienced progression while on a lenalidomide-based regimen in the treatment or maintenance setting, according to clinical criteria

Drugs Used: